What ESC 2021 guidelines say about use of Mineralocorticoid Receptor Antagonist (MRA) in HFrEF?
|
Overview
The European Society of Cardiology (ESC) has recently issued guidelines to include Mineralocorticoid Receptor Antagonist (MRA) besides ACE-I and beta-blockers, in all patients with HFrEF to reduce mortality and the risk of HF hospitalization (class 1A recommendation). The aim of this ESC Guideline is to help health professionals manage people with heart failure (HF) according to the best available evidence.
In this video, Dr. Prem Aggarwal a senior cardiologist, New Delhi gives an insight into the new guidelines and recommendations by ESC while also discussing the treatment modalities for patients with HF.
For more details, check out the below mentioned link:
Speakers
Dr. Prem Aggarwal
MBBS,MD, DNB (Cardiology)
Dr Prem Aggarwal, (DNB Cardiology) is an Cardiologist by profession and also the Co-founder of Medical Dialogues. An avid researcher, he is currently associated with GB Pant Hospital (GIPMER) New Delhi as a PhD Fellow pursuing his research on the topic of Angioplasties on Surgical Rejects
